Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function
J. Clin. Invest. Marco Idzko, et al. 117:464 doi:10.1172/JCI28949 [
Go to this article.]
Figure 5Iloprost treatment of DCs inhibits their potential to prime for Th2 responses. (
A and
B) On day 0, mice received an i.t. injection of vehicle-treated OVA-pulsed DCs (vehicle-OVA-DC), iloprost-treated OVA-pulsed DCs, or unpulsed DCs. From days 10–13, all mice were exposed to OVA aerosols. (
A) BAL fluid was analyzed by flow cytometry. (
B) Hematoxylin and eosin staining of lung sections. (
C) On day –2, mice were injected i.v. with OVA-specific naive T cells from DO11.10 mice. On day 0, mice were instilled i.t. with vehicle-treated OVA-pulsed DCs, iloprost-treated OVA-pulsed DCs, or unpulsed DCs. On day 4, LN cells were collected and cultured in 96-well plates for 4 days. (
D) Supernatants of bone marrow–derived DCs treated overnight with vehicle or different concentrations of iloprost were collected. The presence of IL-4, IL-5, IL-10, IL-12, TNF-α, IL-13, and IFN-γ in the supernatants was analyzed by ELISA. Data are mean ± SEM. *
P < 0.05; **
P < 0.01; ***
P < 0.001.
